NuGen Medical Devices Inc (PK) (NGMDF)

NuGen Medical Devices Files Patent for Dual Spring Technology Enhancing Needle-Free Injection PerformanceMay 28, 2026 1:43 PM
NewsfileToronto, Ontario--(Newsfile Corp. - May 28, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle free drug delivery, today announced the filing of a new patent application (Reference No. P105204NL) covering a new fluid injection technology designed to optimize pressure profiles in needle-free drug delivery systems.The new technology enables a controlled, multi-phase injection profile that delivers the high pressure needed for reliable skin penetration, followed by a lower, more comfortable delivery phase. This approach is intended to improve both clinical consistency and patient comfort-two important factors influencing adoption of needle-free systems.This patent is an important milestone for the Company as it expands its intellectual property portfolio and strengthens its position as an innovator in the needle free drug delivery industry. Solving a Long-Standing Challenge in Needle Free DeliveryTraditional needle free injectors rely on a single actuator to generate the pressure required for injection. This limits the ability to fine tune the injection profile and often forces manufacturers to choose between higher pressure for performance or lower pressure for comfort.NuGen's patent pending design introduces a second actuator, allowing the pressure curve to be shaped more precisely. This enables:A strong initial "piercing phase" for consistent skin penetration; andA gentler "delivery phase" to reduce discomfort and tissue trauma.This dual phase approach is intended to support a broader range of patients and injection scenarios without requiring multiple device variants.Ex-Vivo Testing Demonstrates Strong PerformanceNuGen recently completed ex-vivo testing in partnership with Crux Product Design Ltd., evaluating injection performance in human tissue samples. Imaging analysis using µCT showed that the Company's needle-free injections achieved delivery depths comparable to conventional needle-based injections, within a range consistent with clinically relevant subcutaneous drug delivery. These validation results are an important milestone," said Nicky Canton, Chief Operating Officer of NuGen Medical Devices. "They demonstrate that our advanced pressure-profile technology can deliver clinically meaningful performance in human tissue, giving us strong confidence as we advance our next-generation platforms."Integration Across Next-Generation PlatformThe new technology is expected to play a central role across NuGen's upcoming product pipeline, including: InsuJet V6 platform, designed to improve usability and clinical performance Refill platform, aimed at simplifying daily use through cartridge-based delivery Prefilled nozzle (PFN) platform, supporting pharmaceutical partnerships and biologic drug delivery The innovation builds on NuGen's broader strategy to evolve from a device-focused company into an integrated drug-delivery platform provider.Strengthening NuGen's Intellectual Property and R&D PipelineThe patent filing expands NuGen's intellectual property portfolio and reinforces the Company's long-term competitive positioning in the needle-free drug delivery market. It also aligns with NuGen's R&D roadmap, which focuses on improving clinical performance, enhancing patient experience, and enabling pharmaceutical collaborations.About NuGen Medical DevicesNuGen develops next-generation needle-free devices for subcutaneous drug delivery. Its flagship InsuJet™ system is approved in 42 countries and is designed to improve the lives of millions of people with diabetes worldwide. Websites: insujet.com | insujet.fr | nugenmd.com

LinkedIn: https://www.linkedin.com/company/nugen-medical-devices
Investor Relations: IR@nugenmd.com For further information, please contact:
Ajay Mishra, Chief Financial Officer
+ 1-833-867-5557
ir@nugenmd.comNotice Regarding Forward-Looking InformationNeither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299246 Original: NuGen Medical Devices Files Patent for Dual Spring Technology Enhancing Needle-Free Injection Performance

NuGen Medical Devices Inc. Provides Update on Health Canada LicenseFebruary 5, 2026 5:15 PM
NewsfileToronto, Ontario--(Newsfile Corp. - February 5, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") is initiating a temporary halt on its devices in Canada due to the lapse of its license with Health Canada. The Company's Health Canada Licence became expired due to an untimely certificate renewal. This is not a suspension or cancellation related to regulatory compliance or enforcement action. The temporary status does not constitute a product safety risk. However, to remain compliant with Health Canada medical device regulations, NuGen is currently not selling the affected devices in Canada. A new licence application has already been submitted, and NuGen has been in active communication with Health Canada throughout the process. NuGen is confident the licence will be renewed soon, and sales will resume once the new licence becomes available. The Company's operations elsewhere in the world remain unaffected. The Company will continue to provide updates when available. About NuGen Medical DevicesNuGen develops next-generation needle-free devices for subcutaneous drug delivery. Its flagship InsuJet™ system is approved in 42 countries and is designed to improve the lives of millions of people with diabetes worldwide. Websites: insujet.com | insujet.fr | nugenmd.comLinkedIn: https://www.linkedin.com/company/nugen-medical-devices Investor Relations: IR@nugenmd.com For further information, please contact:
Liang Lin, Chief Executive Officer
+ 1-833-867-5557
ir@nugenmd.comNotice Regarding Forward-Looking Information:Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282935
Original: NuGen Medical Devices Inc. Provides Update on Health Canada License

NuGen Medical Devices Inc. Announces CFO TransitionJanuary 30, 2026 5:15 PM
NewsfileToronto, Ontario--(Newsfile Corp. - January 30, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, announces that Veronique Laberge has resigned from her position as Chief Financial Officer and Corporate Secretary. Her resignation is effective January 31, 2026.The Company has appointed Mr. Ajay Mishra as Chief Financial Officer and Corporate Secretary, effective January 31, 2026. Mr. Mishra will assume responsibility for the Company's financial reporting and related functions.NuGen thanks Ms. Laberge for her contributions during her tenure with the Company.About NuGen Medical DevicesNuGen develops next-generation needle-free devices for subcutaneous drug delivery. Its flagship InsuJet™ system is approved in 42 countries and is designed to improve the lives of millions of people with diabetes worldwide. Websites: insujet.com | insujet.fr | nugenmd.comLinkedIn: https://www.linkedin.com/company/nugen-medical-devices Investor Relations: IR@nugenmd.com For further information, please contact:
Liang Lin, Chief Executive Officer
+ 1-833-867-5557
ir@nugenmd.comNotice Regarding Forward-Looking Information:Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282253
Original: NuGen Medical Devices Inc. Announces CFO Transition

Q3 is Perfekt!